Axel Hoos
Président chez Cancer Research Institute
Profil
Axel Hoos was the founder of Imugene Ltd.
(founded in 2013) and held the title of Independent Non-Executive Director.
He is currently the Co-Chairman at Cancer Research Institute, Director at Nextpoint Therapeutics, Inc. (since 2023), and Trustee at Albert B.
Sabin Vaccine Institute, Inc. Dr. Hoos has previously served as the Chief Executive Officer & Director at Scorpion Therapeutics, Inc. (2021-2024), Senior Director-Clinical Development at Agenus, Inc. (2001-2005), Independent Director at TCR2 Therapeutics, Inc. (2020-2023), and Global Medical Lead-Immunology & Oncology at Bristol Myers Squibb Co. (2005-2011).
He has also held the position of Senior VP & Therapeutic Area Head-Oncology at GlaxoSmithKline Pharmaceuticals Ltd.
Dr. Hoos obtained his doctorate degree from Ruprecht-Karls-Universität Heidelberg in 1997.
Postes actifs de Axel Hoos
| Sociétés | Poste | Début |
|---|---|---|
Albert B. Sabin Vaccine Institute, Inc.
 Albert B. Sabin Vaccine Institute, Inc. Miscellaneous Commercial ServicesCommercial Services Albert B. Sabin Vaccine Institute, Inc. creates solutions to health threats. It works with governments, leading public and private organizations, and academic institutions to provide solutions for some of the pervasive health care challenges. The company was founded in 1993 and is headquartered in Washington, DC. | Directeur/Membre du Conseil | - |
Cancer Research Institute
 Cancer Research Institute Medical/Nursing ServicesHealth Services Cancer Research Institute provides cancer immunotherapy services. The private company is based in New York, NY and has subsidiaries in the United States. The company was founded in 1953. Jill O'Donnell-Tormey has been the CEO of the company since 1987. | Président | - |
Nextpoint Therapeutics, Inc.
 Nextpoint Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Nextpoint Therapeutics, Inc. is a biotech company based in Cambridge, MA. The company is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. The company's innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Nextpoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies. Detlev Biniszkiewicz has been the CEO of the company since 2018. | Directeur/Membre du Conseil | 21/03/2023 |
Anciens postes connus de Axel Hoos
| Sociétés | Poste | Fin |
|---|---|---|
Scorpion Therapeutics, Inc.
 Scorpion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Scorpion Therapeutics, Inc. provides health care services. The company is headquartered in Boston, MA. | Directeur Général | 04/01/2024 |
| TCR2 THERAPEUTICS INC. | Directeur/Membre du Conseil | 01/06/2023 |
| IMUGENE LIMITED | Fondateur | 19/11/2021 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/01/2011 |
| AGENUS INC. | Corporate Officer/Principal | 01/01/2005 |
Formation de Axel Hoos
| Ruprecht-Karls-Universität Heidelberg | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| AGENUS INC. | Health Technology |
| IMUGENE LIMITED | Health Technology |
| GLAXOSMITHKLINE PHARMACEUTICALS LIMITED | Health Technology |
| Entreprise privées | 5 |
|---|---|
Albert B. Sabin Vaccine Institute, Inc.
Albert B. Sabin Vaccine Institute, Inc. Miscellaneous Commercial ServicesCommercial Services Albert B. Sabin Vaccine Institute, Inc. creates solutions to health threats. It works with governments, leading public and private organizations, and academic institutions to provide solutions for some of the pervasive health care challenges. The company was founded in 1993 and is headquartered in Washington, DC. | Commercial Services |
Cancer Research Institute
Cancer Research Institute Medical/Nursing ServicesHealth Services Cancer Research Institute provides cancer immunotherapy services. The private company is based in New York, NY and has subsidiaries in the United States. The company was founded in 1953. Jill O'Donnell-Tormey has been the CEO of the company since 1987. | Health Services |
TCR2 Therapeutics, Inc.
 TCR2 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA. | Health Technology |
Scorpion Therapeutics, Inc.
Scorpion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Scorpion Therapeutics, Inc. provides health care services. The company is headquartered in Boston, MA. | Health Technology |
Nextpoint Therapeutics, Inc.
Nextpoint Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Nextpoint Therapeutics, Inc. is a biotech company based in Cambridge, MA. The company is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. The company's innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Nextpoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies. Detlev Biniszkiewicz has been the CEO of the company since 2018. | Commercial Services |
